Biosimilar Market - Detailed Analysis and Forecast by 2023 - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Biosimilar Market - Detailed Analysis and Forecast by 2023

Description:

Infinium Global Research has added a new report on Global Biosimilar Market. The report predicts the market size of Biosimilar is expected to reach XX billion by 2023. – PowerPoint PPT presentation

Number of Views:2

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Biosimilar Market - Detailed Analysis and Forecast by 2023


1
Biosimilar Market Global Industry Analysis,
Trends, Market Size Forecasts up to 2023
2
A latest report has been added to the wide
database of Biosimilar Market by Infinium Global
Research. This report studies the Biosimilar
Market by product (human growth hormones,
monoclonal antibodies, insulin, peptides,
erythropoietin and others), application,
(oncology, chronic and autoimmune diseases,
growth hormone deficiency, infectious diseases
and others) market status and outlook of global
and major regions, from manufacturers, and end
industries. The objective of the study is to
identify market sizes of different segments
countries in recent years and to forecast the
values for the next six years. Biosimilar Market
provides opportunities in micro markets for
stakeholders to invest along with the detailed
analysis of competitive landscape, latest
trends, and product offerings of the major
companies in the Biosimilar Market. According to
the report the Global Biosimilar Market is
projected to grow at a CAGR between 25.0 to
26.0 in terms of value over the period of
2017-2023. A product is termed as biosimilar
product, if it is a biological product with
similar characteristics as that of a reference
biological product, which possesses approval from
agencies such as FDA. There would not be any
major clinical difference in effectiveness and
safety as that of reference product. Biosimilar
products are made of complex molecules with high
molecular weight produced through genetic
engineering in living cells. Biologics drugs are
costlier than respective chemical drugs.
Biosimilar drugs can save around 30 to 40 in
terms of price relative to the respective
biologics drugs. Biosimilar are useful for the
treatment of illnesses such as anemia, autoimmune
diseases, cancer, diabetes, growth hormone
deficiencies, hematological diseases, kidney
failure, rheumatoid arthritis and others. For the
manufacturing of biosimilar, manufacturers have
to develop environments that are ideal for the
living cells, which remain sensitive to
environmental conditions. Moreover, they need to
develop distinctive process to entice the living
cells for producing similar outcome to a
prevalent biological treatment. The substitution
of biological drugs with biosimilar drugs can
save lot of money for public health care sector
and patients. The regulatory authorities in
developed nations are promoting biosimilar
products. Increasing awareness about biosimilar
among the patients and doctors is a major factor
for the growth of the global biosimilar market.
Presence of large number of geriatric population
is expected to aid the growth of the global
biosimilar market during the forecast period, as
they need treatment for various chronical
illnesses. Increasing number of patients with
chronic illnesses such as diabetes and cancer
drive the demand for effective patented biologics
medicines. Due to the lower cost, biosimilar
medicines are expected attain more demand and
drive the growth of the global biosimilar market
during the forecast period. Segments related to
diabetes medicine and oncologies are expected to
attain faster growth during the forecast
period. Expiry of patents of various blockbuster
drugs is a major factor for the growth of the
global biosimilar market, as it is expected to
provide the opportunities for the smaller
pharmaceutical manufacturer to produce
biosimilars in those segments. The reimbursement
policies of various governments and the
increasing interests from the insurance companies
3
are expected to make biosimilars affordable to
more people and drive the growth of the global
biosimilar market. Non- original biologics and
bio betters provide major challenge to the
biosimilar market. Non-original biologics are
duplicate products of reference biologics found
in markets with lesser regulations or relaxed
intellectual property protection. Though bio
betters are regulated, as stepwise upgrade of
innovator molecules, they are finding space in
the drugs market. The lack of clear guidelines
for the interchangeability or substitution of
drugs with bio-similar is a restraint for the
growth of the biosimilar market. The high
manufacturing cost and complexity of production,
along with the unclear regulatory policies in
many countries are expected to be the major
restraints for the global biosimilar market
during the forecast period. However, due to the
lower prices of biosimilars, the treatment for
many diseases such as diabetes , rheumatoid
arthritis and types of cancers, are anticipated
to become affordable in developing countries and
it provide opportunities for major players in the
global biosimilar market to expand during the
forecast period. Moreover, strategic partnerships
between biosimilar manufacturers, manufacturing
of multiple biosimilar products in same
production facility and outsourcing of
manufacturing to third parties are expected to
help the major players to expand faster during
the forecast period. Segments Covered The
report segments the global biosimilar market by
product, application and region. On the basis of
product, the market is segmented as human growth
hormones, monoclonal antibodies, insulin,
peptides, erythropoietin and others. Based on
application, the market is segmented as oncology,
chronic and autoimmune diseases, growth hormone
deficiency, infectious diseases and
others. Geographic Coverage and Analysis The
report provides regional analysis covering
geographies such as North America, Europe,
Asia-Pacific, and Rest of the World. With the
maximum number of approved biosimilars, European
market is the major biosimilar market in the
world. Countries such as France, Germany, Italy
and United Kingdom drive the growth of the
European biosimilar market with high demand for
low cost alternatives for biologics medicines.
Expiry of patents for certain biologics medicines
and presence of good regulatory frameworks set
up by European Medical Association are expected
to aid the growth of the European biosimilar
market, during the forecast period. Asia-Pacific
region has significant biosimilars in use due to
the relaxed regulations in various countries.
Due to the presence of large population and need
for low cost alternative medicines for
4
  • various diseases in countries such as China,
    India, South Korea and others drive the growth of
    biosimilar market in Asia- Pacific. As the rate
    of approvals for biosimilars are increasing at a
    faster pace in the U.S., the North-American
    region is expected to become the fastest growing
    biosimilar market during the forecast period. The
    pharmaceutical companies in the North American
    region are expected to make use of the research
    and development initiatives related to
    biosimilars and expiring biologics patents for
    increasing the production of biosimilar medicine
    to meet the requirements of the geriatric
    population and the patients with chronic
    illnesses depending upon the reimbursement and
    insurance policies.
  • Companies Profiled
  • Allergan plc,
  • BIOCAD,
  • Biocon,
  • BioXpress Therapeutics SA,
  • Boehringer Ingelheim GmbH,
  • Celltrion Inc.,
  • Coherus BioSciences, Inc,
  • Dr. Reddys Laboratories Ltd.,
  • Genor BioPharma Co. Ltd,
  • Intas Pharmaceuticals Limited,
  • Novartis AG,
  • Pfizer, Inc.,
  • Reliance Life Sciences.

5
Report Highlights The report provides deep
insights on demand forecasts, market trends and
micro and macro indicators. In addition, this
report provides insights on the factors that are
driving and restraining the demand of biosimilar
globally as well as regionally. Moreover,
IGR-Growth Matrix analysis given in the report
brings an insight on the investment areas that
existing or new market players can consider. The
report provides insights into the market using
analytical tools such as Porters five forces
analysis and DRO analysis of biosimilar market.
Moreover, the study highlights current market
trends and provides forecast from 2017 to 2023.
We also have highlighted future trends in the
biosimilar market that will impact the demand
during the forecast period. Moreover, the
competitive analysis given in each regional
market brings an insight on the market share of
the leading players. Additionally, the analysis
highlights rise and fall in the market shares of
the key players in the market. About
Us Infinium Global Research and Consulting
Solutions is started with a single motto of being
business partner of first choice. We at Infinium
work on the strengths of our clients to ensure we
help them consolidate their market position. We
firmly believe in the fact that if you are able
to develop newer opportunities then you find
there is no dearth of opportunities for you. With
our strategic research approaches and deep dive
in the market segments, we try to find out new
opportunities that our clients can encash with
their existing resources. Our experts with over
100 years of cumulative experience in research
offer the best in the industry services to our
clients to ensure that they achieve their
business goals. Browse Detailed TOC, Description
and Companies Mentioned in Report _at_
https//www.infiniumglobalresearch.com/healthcare_
medical_devices/biosimilar_market
About PowerShow.com